Romosozumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), CONITEC (Brazil) and DMC (Denmark), among others, recommended or restricted romosozumab, while CIPM (Spain) and HAS (France) did not recommend it.
Assessment has run over 6.2 years, from 2018 at PBAC (Australia) to 16 Sep 2024 at CONITEC (Brazil).
PBAC (Australia) changed its position: not recommended in 2018, recommended by 2024, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
The file is active: 4 of 20 records date from 2023 or later.
3 distinct indication wordings are recorded for romosozumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
6 of these 20 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess romosozumab, in 2018; AOTMIT (Poland) did not open a file until 30 Jan 2024 — a wide spread of 5.5 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 8 of 20 dated records fall in 2020 alone.
3 of the 13 agencies here assessed romosozumab more than once, PBAC (Australia) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
romosozumab has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for romosozumab reads 9 recommended, 5 not recommended, 4 restricted and 1 advice, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 16 Sep 2024 | Tratamento de osteoporose grave e em falha terapêutica. | incorporated into SUS | source |
| AOTMIT (Poland) | 30 Jan 2024 | Evenity reimbursement recommendation | recommended conditionally | source |
| PBAC (Australia) | 2022 | Osteoporosis | Not Recommended | source |
| NICE (England) | 25 May 2022 | NICE TA791 | recommended (optimised) | source |
| CIPM (Spain) | 5 May 2022 | Indicaciones terapéuticas autorizadas: Evenity está indicado en el tratamiento de la osteoporosis grave en mujeres posme… | not financed by the SNS · art. 92 c, d | source |
15 further decisions for romosozumab, across 11 agencies, are not shown here. They link to 9 further source documents.
Related molecules
- denosumab — same ATC class M05B — Bone diseases
- burosumab — same ATC class M05B — Bone diseases
- zoledronic acid — same ATC class M05B — Bone diseases
- vosoritide — same ATC class M05B — Bone diseases
- dibotermin alfa — same ATC class M05B — Bone diseases
- ibandronic acid — same ATC class M05B — Bone diseases
Coverage: 20 decisions for romosozumab from 13 agencies, 2018 to 2024. Data to 7 Sep 2026. ATC class M05B — Bone diseases. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.